Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

cemiplimab × Tumor-Agnostic × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 12 Dermatologic 9 Head & Neck 7 Gastrointestinal 3 Endocrine 3 Sarcoma 2 Other solid neoplasm 2 Lymphoid 2 CNS 2 Tumor-Agnostic 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Gynecologic 1 Genitourinary 1 Breast 1

Conditions

Neoplasm Metastasis 1

Interventions

Specimen Handling 18 Biopsy 17 pembrolizumab 14 Magnetic Resonance Spectroscopy 14 Carboplatin 8 Paclitaxel 7 Nivolumab 7 Cisplatin 7 Bevacizumab 7 atezolizumab 6 Gemcitabine 6 Taxes 5 Pemetrexed 5 Capecitabine 5 trastuzumab deruxtecan 4 Docetaxel 4 Blood Specimen Collection 4 relatlimab 3 osimertinib 3 nilotinib 3 ipatasertib 3 durvalumab 3 X-Rays 3 Trastuzumab 3 Surveys and Questionnaires 3 Standard of Care 3 Radiosurgery 3 Oxaliplatin 3 Leucovorin 3 Ipilimumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06790602 2026-04-09

SWITCH

University of California, San Diego

Phase 2 Recruiting

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡